Clinical Trials Logo

Danon Disease clinical trials

View clinical trials related to Danon Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06214507 Recruiting - Danon Disease Clinical Trials

Danon Disease Natural History Study

Start date: December 20, 2023
Phase:
Study type: Observational

The goal of this international observational study is to learn about the natural history of Danon disease in male patients >8 years of age. The key objectives include assessing change over time in cardiac structure (left ventricular mass and wall thickness), cardiac biomarkers, symptoms, and quality of life and the incidence of clinical events such as HF hospitalization, cardiac transplantation, and death.

NCT ID: NCT06092034 Recruiting - Danon Disease Clinical Trials

A Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Start date: September 5, 2023
Phase: Phase 2
Study type: Interventional

This is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene, in male patients with Danon Disease.

NCT ID: NCT03766386 Recruiting - Danon Disease Clinical Trials

The Natural History of Danon Disease

Start date: November 30, 2018
Phase:
Study type: Observational [Patient Registry]

Danon disease (DD) is a rare, X-linked disorder associated with severe cardiomyopathy, and in many cases, skeletal myopathy, and cognitive impairment caused by mutations in the LAMP2 gene. There is still uncertainty regarding the natural history of DD because of its rarity. This study aims to determine the natural history of DD through the collection and analysis of retrospective and prospective data. To achieve this, the investigators will perform surveys and obtain medical records from DD patients. The same cohort of patients will also be assessed by a multidisciplinary team with expertise in DD (cardiologist, neurologist, ophthalmologist, psychologist, geneticist) at the University of California, San Diego. All patients with DD are eligible, including those who underwent a heart transplant. Additionally, data and records from deceased patients will provide valuable retrospective data for this study.